Liver Immune Status Index (LISI) as a prognostic marker for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most challenging cancers to treat, primarily due to its high recurrence rates following curative interventions such as hepatectomy[1]. The prognosis of HCC is influenced by various factors, including vascular invasion, liver fibrosis, and the patient’s immune response[2]. In particular, the role of liver-resident natural killer (NK) cells has garnered attention for their ability to target and eliminate circulating tumor cells (CTCs), which contribute to cancer recurrence[3,4]. This highlights the importance of identifying reliable prognostic markers that reflect the immune system’s efficacy in combating HCC. A recent multi-institutional retrospective study by Imaoka et al evaluated the Liver Immune Status Index (LISI) as a prognostic tool in a cohort of 1337 patients undergoing primary hepatectomy for HCC[5]. Their findings revealed that patients with a low LISI had a significantly lower 2-year recurrence rate (approximately 20%) compared to those with a high LISI (about 48%). Moreover, the 2-year overall survival rate was markedly higher in patients with a low LISI, reaching around 75%, versus only 45% in patients with high LISI. The study further demonstrated that LISI had a predictive accuracy (AUC) of 0.72 for 2-year recurrence rates, outperforming other established prognostic indices like the Albumin-Bilirubin (ALBI) grade (AUC 0.64) and FIB-4 index (AUC 0.61). These data suggest that LISI serves as a powerful and independent predictor of postoperative outcomes in HCC, especially in patients with vascular invasion, offering clinicians a valuable tool for risk stratification and personalized patient management. The liver immune microenvironment plays a pivotal role in determining the progression and recurrence of HCC[6]. NK cells, which are abundant in the liver, possess potent antitumor activities, including inducing apoptosis in tumor cells and regulating immune responses[7]. Their ability to target CTCs makes them crucial in preventing both intrahepatic and distant metastasis after hepatectomy[8]. However, factors such as liver fibrosis and cirrhosis can impair NK cell activity, diminishing the body’s natural defense against HCC spread[9]. The interplay between NK cell function and liver fibrosis directly impacts the recurrence risk in HCC patients[10]. Therefore, assessing the immune status of the liver, which reflects the functional capacity of NK cells, provides a more nuanced understanding of a patient’s prognosis. LISI serves as an innovative method for gauging liver immune competence, thereby offering insights into potential recurrence risks. Several prognostic indices, such as the Albumin-Bilirubin (ALBI) grade, the Fibrosis-4 (FIB-4) index, and the Geriatric Nutritional Risk Index (GNRI), have been used to evaluate the prognosis of HCC patients[11,12]. These indices incorporate parameters like liver function, fibrosis level, and nutritional status, which are known to influence the likelihood of recurrence and overall survival. However, their predictive accuracy can be limited, particularly in cases where the immune response plays a central role. LISI stands out due to its focus on the immune aspect of HCC prognosis[13]. By combining factors such as albumin levels, body mass index (BMI), and the FIB-4 index, LISI provides a comprehensive assessment of liver immune status. This makes it a more holistic tool for evaluating recurrence risks, especially in the early postoperative period when immune competence is crucial for preventing tumor dissemination. One of the strengths of using LISI is its potential to be integrated into broader prognostic models for HCC. When combined with tumor burden markers, such as the tumor burden score and alpha-fetoprotein levels, LISI can enhance the accuracy of predicting long-term outcomes in HCC patients[14]. These comprehensive models can guide clinicians in risk stratification, enabling more personalized treatment plans and follow-up strategies. The integration of LISI into predictive models underscores the importance of a multidimensional approach to HCC prognosis. By incorporating immune status, tumor biology, and liver function, these models offer a more precise risk assessment, facilitating tailored interventions and improved patient outcomes. The introduction of LISI as a prognostic marker has significant implications for the management of HCC. Its ability to reflect liver immune status offers a noninvasive means of identifying patients at higher risk for recurrence, enabling earlier interventions such as adjuvant therapies or intensified monitoring. This could improve postoperative management and potentially reduce the rate of HCC recurrence. Moreover, the use of LISI as a surrogate marker for liver NK cell activity opens avenues for future research focused on enhancing immune responses in HCC. Investigating therapies that boost NK cell function, combined with strategies that reduce fibrosis, may hold the key to improving outcomes in HCC patients. Validating LISI across diverse populations and settings will be crucial for establishing its utility in routine clinical practice. In conclusion, LISI offers a promising tool for predicting postoperative outcomes in hepatocellular carcinoma by providing a measure of the liver’s immune competence. Its ability to stratify patients based on recurrence risks highlights its potential role in guiding personalized treatment strategies. As research continues to uncover the intricate relationship between immune status and HCC prognosis, LISI is poised to become an integral component of HCC management, contributing to more effective, individualized care for this challenging patient population.